In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $3.83.
Caufield covers the Healthcare sector, focusing on stocks such as Ocuphire Pharma, 4D Molecular Therapeutics, and IVERIC bio. According to TipRanks, Caufield has an average return of 41.9% and a 71.43% success rate on recommended stocks.
Currently, the analyst consensus on Ocuphire Pharma is a Moderate Buy with an average price target of $18.00.
See Insiders’ Hot Stocks on TipRanks >>
OCUP market cap is currently $74.91M and has a P/E ratio of -3.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Read More on OCUP:
